Ocular and systemic safety of bevacizumab and ranibizumab in patients with neovascular age-related macular degeneration

Current Opinion in Ophthalmology

Volumn 24, Issue 3, 2013, Pages 205-212

  Johnson, Davin ^a   Sharma, Sanjay ^a  

^a HOTEL DIEU HOSPITAL   (Canada)

Author keywords

Bevacizumab; Ranibizumab; Vascular Endothelial Growth Factor

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB;

ACUTE INTRAOCULAR INFLAMMATION; ARTERIAL THROMBOEMBOLISM; CEREBROVASCULAR ACCIDENT; CONJUNCTIVA DISEASE; CONJUNCTIVA INJECTION; CONJUNCTIVAL HEMORRHAGE; CORNEA ABRASION; CORNEA DISEASE; DRUG ABSORPTION; DRUG DOSAGE FORM COMPARISON; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; ENDOPHTHALMITIS; EXUDATIVE MACULAR DEGENERATION; EYE INFLAMMATION; GASTROINTESTINAL DISEASE; HUMAN; HYPERTENSION; INFECTIVE ENDOPHTHALMITIS; INFLAMMATION; INTRAOCULAR PRESSURE ABNORMALITY; PATHOGENESIS; PRIORITY JOURNAL; RETINA DETACHMENT; RETINA HEMORRHAGE; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA HEMORRHAGE; RETINA TEAR; REVIEW; SUBCONJUNCTIVAL HEMORRHAGE; TRAUMATIC CATARACT; VEIN THROMBOSIS; VITREOUS HEMORRHAGE;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; HUMANS; INTRAVITREAL INJECTIONS; OFF-LABEL USE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 84876281638     PISSN: 10408738     EISSN: 15317021     Source Type: Journal    
DOI: 10.1097/ICU.0b013e32835f8ec0     Document Type: Review

References (120)

1. Keenan TD, Wotton CJ, Goldacre MJ. Trends over time and geographical variation in rates of intravitreal injections in England. Br J Ophthalmol 2012; 96:413-418.
2. Campbell RJ, Bronskill SE, Bell CM, et al. Rapid expansion of intravitreal drug injection procedures, 2000 to 2008: a population-based analysis. Arch Ophthalmol 2010; 128:359-362.
3. Ramulu PY, Do DV, Corcoran KJ, et al. Use of retinal procedures in Medicare beneficiaries from 1997 to 2007. Arch Ophthalmol 2010; 128:1335-1340.
4. Lien S, Lowman HB. Therapeutic anti-VEGF antibodies. Handb Exp Pharmacol 2008; 131-150.
5. Martin DF, Maguire MG, Ying GS, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011; 364: 1897-1908..
6. Martin DF, Maguire MG, Fine SL, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 2012; 119:1388-1398. The CATT trial is a well designed RCT providing 2 year efficacy and safety data for bevacizumab vs. ranibizumab in the setting of neovascular AMD.
7. IVAN Study Investigators. Alternative treatments to inhibit VEGF in agerelated choroidal neovascularization (IVAN). ARVO 2012; 2012.
8. Gamulescu MA, Radeck V, Lustinger B, et al. Bevacizumab versus ranibizumab in the treatment of exudative age-related macular degeneration. Int Ophthalmol 2010; 30:261-266.
9. Subramanian ML, Abedi G, Ness S, et al. Bevacizumab vs. ranibizumab for age-related macular degeneration:1-year outcomes of a prospective, double-masked randomised clinical trial. Eye (Lond) 2010; 24:1708-1715.
10. Biswas P, Sengupta S, Choudhary R, et al. Comparative role of intravitreal ranibizumab versus bevacizumab in choroidal neovascular membrane in agerelated macular degeneration. Indian J Ophthalmol 2011; 59:191-196.
11. Landa G, Amde W, Doshi V, et al. Comparative study of intravitreal bevacizumab (Avastin) versus ranibizumab (Lucentis) in the treatment of neovascular age-related macular degeneration. Ophthalmologica 2009; 223:370-375.
12. Stepien KE, Rosenfeld PJ, Puliafito CA, et al. Comparison of intravitreal bevacizumab followed by ranibizumab for the treatment of neovascular agerelated macular degeneration. Retina 2009; 29:1067-1073.
13. Fong DS, Custis P, Howes J, Hsu JW. Intravitreal bevacizumab and ranibizumab for age-related macular degeneration a multicenter, retrospective study. Ophthalmology 2010; 117:298-302.
14. Chakravarthy U, Harding SP, Rogers CA, et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology 2012; 119:1399-1411. The IVAN trial is a well designed RCT providing 1 year efficacy and safety data for bevacizumab vs. ranibizumab in the setting of neovascular AMD.
15. Chang TS, Kokame G, Casey R, et al. Short-term effectiveness of intravitreal bevacizumab versus ranibizumab injections for patients with neovascular age-related macular degeneration. Retina 2009; 29:1235-1241.
16. Tufail A, Patel PJ, Egan C, et al. Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study. Br Med J 2010; 340:c2459.17.
17. Schmid-Kubista KE, Krebs I, Ansari-Shahrezaei S, et al. Comparing treatment of neovascular age-related macular degeneration with sequential intravitreal Avastin andMacugen versus intravitreal mono-therapy: a pilot study. Curr Eye Res 2011; 36:958-963.
18. Rudnisky CJ, Liu C, Ng M, et al. Intravitreal bevacizumab alone versus combined verteporfin photodynamic therapy and intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration: visual acuity after 1 year of follow-up. Retina 2010; 30:548-554.
19. Ahmadieh H, Taei R, Riazi-Esfahani M, et al. Intravitreal bevacizumab versus combined intravitreal bevacizumab and triamcinolone for neovascular agerelated macular degeneration: six-month results of a randomized clinical trial. Retina 2011; 31:1819-1826.
20. Bashshur ZF, Schakal A, Hamam RN, et al. Intravitreal bevacizumab vs. verteporfin photodynamic therapy for neovascular age-related macular degeneration. Arch Ophthalmol 2007; 125:1357-1361.
21. Sacu S, Michels S, Prager F, et al. Randomised clinical trial of intravitreal Avastin vs. photodynamic therapy and intravitreal triamcinolone: long-term results. Eye (Lond) 2009; 23:2223-2227.
22. Nguyen QD, Schachar RA, Nduaka CI, et al. Evaluation of the siRNA PF-04523655 versus ranibizumab for the treatment of neovascular agerelated macular degeneration (MONET Study). Ophthalmology 2012; 119: 1867-1873.
23. Flaxel C, Schain MB, Hamon SC, Francis PJ. Prospective randomized controlled trial of combination ranibizumab (Lucentis) and bromfenac (Xibrom) for neovascular age-related macular degeneration: a pilot study. Retina 2012; 32:417-423.
24. Abraham P, Yue H, Wilson L. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2. Am J Ophthalmol 2010; 150:315-324; e1.
25. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular agerelated macular degeneration. N Engl J Med 2006; 355:1419-1431.
26. Brown DM, Michels M, Kaiser PK, et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: twoyear results of the ANCHOR study. Ophthalmology 2009; 116:57-65; e5.
27. Kaiser PK, Boyer DS, Cruess AF, et al. Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelvemonth results of the DENALI study. Ophthalmology 2012; 119:1001-1010.
28. Li X, Hu Y, Sun X, et al. Bevacizumab for neovascular age-related macular degeneration in China. Ophthalmology 2012; 119:2087-2093.
29. Suzuki M, Gomi F, Sawa M, et al. Bevacizumab treatment for choroidal neovascularization due to age-related macular degeneration in Japanese patients. Ophthalmol 2010; 54:124-128.
30. Costagliola C, Semeraro F, Cipollone U, et al. Changes in neovascular choroidal morphology after intravitreal bevacizumab injection: prospective trial on 156 eyes throughout 12-month follow-up. Graefes Arch Clin Exp Ophthalmol 2009; 247:1031-1037.
31. Leydolt C, Michels S, Prager F, et al. Effect of intravitreal bevacizumab (Avastin) in neovascular age-related macular degeneration using a treatment regimen based on optical coherence tomography: 6-and 12-month results. Acta Ophthalmol 2010; 88:594-600.
32. Mekjavic PJ, Kraut A, Urbancic M, et al. Efficacy of 12-month treatment of neovascular age-related macular degeneration with intravitreal bevacizumab based on individually determined injection strategies after three consecutive monthly injections. Acta Ophthalmol 2011; 89:647-653.
33. Krebs I, Lie S, Stolba U, et al. Efficacy of intravitreal bevacizumab (Avastin) therapy for early and advanced neovascular age-related macular degeneration. Acta Ophthalmol 2009; 87:611-617.
34. Fong KC, Kirkpatrick N, Mohamed Q, Johnston RL. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration using a variable frequency regimen in eyes with no previous treatment. Clin Experiment Ophthalmol 2008; 36:748-755.
35. Chen CY, Wong TY, Heriot WJ. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration: a short-term study. Am J Ophthalmol 2007; 143:510-512.
36. Levy J, Shneck M, Rosen S, et al. Intravitreal bevacizumab (avastin) for subfoveal neovascular age-related macular degeneration. Int Ophthalmol 2009; 29:349-357.
37. Madhusudhana KC, Hannan SR, Williams CP, et al. Intravitreal bevacizumab (Avastin) for the treatment of choroidal neovascularization in age-related macular degeneration: results from 118 cases. Br J Ophthalmol 2007; 91:1716-1717.
38. Emerson MV, Lauer AK, Flaxel CJ, et al. Intravitreal bevacizumab (Avastin) treatment of neovascular age-related macular degeneration. Retina 2007; 27:439-444.
39. Aggio FB, Farah ME, Silva WC, Melo GB. Intravitreal bevacizumab for exudative age-related macular degeneration after multiple treatments. Graefes Arch Clin Exp Ophthalmol 2007; 245:215-220.
40. Carneiro AM, Falcao MS, Brandao EM, Falcao-Reis FM. Intravitreal bevacizumab for neovascular age-related macular degeneration with or without prior treatment with photodynamic therapy: one-year results. Retina 2010; 30:85-92.
41. Goff MJ, Johnson RN, McDonald HR, et al. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration. Retina 2007; 27:432-438.
42. Arevalo JF, Sanchez JG, Wu L, et al. Intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration at twentyfour months: the Pan-American Collaborative Retina Study. Ophthalmology 2010; 117:1974-1981; e1.
43. Bashshur ZF, Haddad ZA, Schakal A, et al. Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: a one-year prospective study. Am J Ophthalmol 2008; 145:249-256.
44. Bashshur ZF, Haddad ZA, Schakal AR, et al. Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: the second year of a prospective study. Am J Ophthalmol 2009; 148:59-65; e1.
45. Costagliola C, Romano M, Corte MD, et al. Intravitreal bevacizumab for treatment-naive patients with subfoveal occult choroidal neovascularization secondary to age-related macular degeneration: a 12-month follow-up study. Retina 2009; 29:1227-1234.
46. Furino C, Boscia F, Recchimurzo N, et al. Intravitreal bevacizumab for treatment-naive subfoveal occult choroidal neovascularization in age-related macular degeneration. Acta Ophthalmol 2009; 87:404-407.
47. Cleary CA, Jungkim S, Ravikumar K, et al. Intravitreal bevacizumab in the treatment of neovascular age-related macular degeneration, 6-and 9-month results. Eye (Lond) 2008; 22:82-86.
48. Modarres M, Naseripour M, Falavarjani KG, et al. Intravitreal injection of 2.5mg versus 1. 25 mg bevacizumab (Avastin) for treatment of CNV associated with AMD Retina 2009; 29:319-324.
49. Lazic R, Gabric N. Intravitreally administered bevacizumab (Avastin) in minimally classic and occult choroidal neovascularization secondary to age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2007; 245:68-73.
50. Sonmez K, Sonmez PA, Ozkan SS, Atmaca LS. One-year outcomes of less frequent bevacizumab in age-related macular degeneration. Retina 2011; 31:645-653.
51. Algvere PV, Steen B, Seregard S, Kvanta A. A prospective study on intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration of different durations. Acta Ophthalmol 2008; 86:482-489.
52. Dunavoelgyi R, Sacu S, Eibenberger K, et al. Retreatment with antivascular endothelial growth factor therapy based on changes in visual acuity after initial stabilization of neovascular age-related macular degeneration: 3-year follow-up results. Retina 2012; 32:1471-1479.
53. Luu ST, Gray T, Warrier SK, et al. Retrospective study of an as required dosing regimen of intravitreal bevacizumab in neovascular age-related macular degeneration in an Australian population. Clin Experiment Ophthalmol 2010; 38:659-663.
54. Rich RM, Rosenfeld PJ, Puliafito CA, et al. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina 2006; 26:495-511.
55. Arias L, Caminal JM, Casas L, et al. A study comparing two protocols of treatment with intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Br J Ophthalmol 2008; 92:1636-1641.
56. Melamud A, Stinnett S, Fekrat S. Treatment of neovascular age-related macular degeneration with intravitreal bevacizumab: efficacy of three consecutive monthly injections. Am J Ophthalmol 2008; 146:91-95.
57. Lai TY, Liu DT, Chan KP, et al. Visual outcomes and growth factor changes of two dosages of intravitreal bevacizumab for neovascular age-related macular degeneration: a randomized, controlled trial. Retina 2009; 29:1218-1226.
58. Kumar A, Sahni JN, Stangos AN, et al. Effectiveness of ranibizumab for neovascular age-related macular degeneration using clinician-determined retreatment strategy. Br J Ophthalmol 2011; 95:530-533.
59. Schmidt-Erfurth U, Eldem B, Guymer R, et al. Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study. Ophthalmology 2011; 118:831-839.
60. Singer MA, Awh CC, Sadda S, et al. HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology 2012; 119:1175-1183.
61. Saito M, Iida T, Kano M. Intravitreal ranibizumab for exudative age-related macular degeneration with good baseline visual acuity. Retina 2012; 32:1250-1259.
62. Tano Y, Ohji M. Long-term efficacy and safety of ranibizumab administered pro re nata in Japanese patients with neovascular age-related macular degeneration in the EXTEND-I study. Acta Ophthalmol 2011; 89:208-217.
63. Kang S, Roh YJ. One-year results of intravitreal ranibizumab for neovascular age-related macular degeneration and clinical responses of various subgroups. Jpn J Ophthalmol 2009; 53:389-395.
64. Boyer DS, Heier JS, Brown DM, et al. A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration. Ophthalmology 2009; 116:1731-1739.
65. Querques G, Azrya S, Martinelli D, et al. Ranibizumab for exudative agerelated macular degeneration: 24-month outcomes from a single-centre institutional setting. Ophthalmol 2010; 94:292-296.
66. Kaiser R, Gupta O, Regillo C, et al. Ranibizumab for eyes previously treated with pegaptanib or bevacizumab without clinical response. Ophthalmol Surg Lasers Imaging 2012; 43:13-19.
67. McKibbin M, Papastefanou V, Matthews B, et al. Ranibizumab monotherapy for sub-foveal haemorrhage secondary to choroidal neovascularisation in age-related macular degeneration. Eye (Lond) 2010; 24:994-998.
68. Holz FG, Amoaku W, Donate J, et al. Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study. Ophthalmology 2011; 118:663-671.
69. Lalwani GA, Rosenfeld PJ, Fung AE, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol 2009; 148:43-58; e1.
70. Shona O, Gupta B, Vemala R, Sivaprasad S. Visual acuity outcomes in ranibizumab-treated neovascular age-related macular degeneration; stratified by baseline vision. Clin Experiment Ophthalmol 2011; 39:5-8.
71. Arias L, Ruiz-Moreno JM, Gomez-Ulla F, et al. A1-year retrospective review of ranibizumab for naive nonsubfoveal choroidal neovascularization secondary to age-related macular degeneration. Retina 2009; 29:1444-1449.
72. Sharma S, Johnson D, Abouammoh M, et al. Rate of serious adverse effects in a series of bevacizumab and ranibizumab injections. Can J Ophthalmol 2012; 47:275-279. In this retrospective series from our center an increased risk of both acute intraocular inflammation and arterial thromboembolic events was seen following bevacizumab compared to ranibizumab injections.
73. Mezad-Koursh D, Goldstein M, Heilwail G, et al. Clinical characteristics of endophthalmitis after an injection of intravitreal antivascular endothelial growth factor. Retina 2010; 30:1051-1057.
74. Bakri SJ, Larson TA, Edwards AO. Intraocular inflammation following intravitreal injection of bevacizumab. Graefes Arch Clin Exp Ophthalmol 2008; 246:779-781.
75. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006; 355:1432-1444.
76. Georgopoulos M, Polak K, Prager F, et al. Characteristics of severe intraocular inflammation following intravitreal injection of bevacizumab (Avastin). Br J Ophthalmol 2009; 93:457-462.
77. Johnson D, Hollands H, Hollands S, Sharma S. Incidence and characteristics of acute intraocular inflammation after intravitreal injection of bevacizumab: a retrospective cohort study. Can J Ophthalmol 2010; 45:239-242.
78. Wickremasinghe SS, Michalova K, Gilhotra J, et al. Acute intraocular inflammation after intravitreous injections of bevacizumab for treatment of neovascular age-related macular degeneration. Ophthalmology 2008; 115:1911-1915.
79. Chong DY, Anand R, Williams PD, et al. Characterization of sterile intraocular inflammatory responses after intravitreal bevacizumab injection. Retina 2010; 30:1432-1440.
80. Sato T, Emi K, Ikeda T, et al. Severe intraocular inflammation after intravitreal injection of bevacizumab. Ophthalmology 2010; 117:512-516; 6 e1-2.
81. Fielden M, Nelson B, Williams G, et al. Aucte intraocular inflammation following intravitreal injection of bevacizumab: a cluster of cases. Canadian Ophthalmology Society Annual Conference and Exhibition. Toronto, 2009. Can J Ophthalmol 2010; 45:239-242.
82. Ness T, Feltgen N, Agostini H, et al. Toxic vitreitis outbreak after intravitreal injection. Retina 2010; 30:332-338.
83. Yamashiro K, Tsujikawa A, Miyamoto K, et al. Sterile endophthalmitis after intravitreal injection of bevacizumab obtained from a single batch. Retina 2010; 30:485-490.
84. Hermeling S, Crommelin DJ, Schellekens H, Jiskoot W. Structure- immunogenicity relationships of therapeutic proteins. Pharm Res 2004; 21:897-903.
85. Bakri SJ, Snyder MR, Reid JM, et al. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 2007; 114:855-859.
86. Bakri SJ, Snyder MR, Reid JM, et al. Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology 2007; 114:2179-2182.
87. Brooks SA. Appropriate glycosylation of recombinant proteins for human use: implications of choice of expression system. Mol Biotechnol 2004; 28:241-255.
88. Mamalis N, Edelhauser HF, Dawson DG, et al. Toxic anterior segment syndrome. J Cataract Refract Surg 2006; 32:324-333.
89. Hall R, Lodha N, Mitchell P, et al. Incidence of ocular complications following intravitreal bevacizumab (Avastin) injections. Toronto: Canadian Ophthalmology Society Annual Conference and Exhibition; 2009.
90. Holland S, Ma P, Maberley D, et al. Outbreak of acute intraocular inflammation after bevacizumab intravitreal injection: an epidemiological investigation. Toronto: Canadian Ophthalmology Society Annual Conference and Exhibition; 2009.
91. Hoffman-La Roche Limited. Important safety information on Avastin (bevacizumab).
92. Pilli S, Kotsolis A, Spaide RF, et al. Endophthalmitis associated with intravitreal antivascular endothelial growth factor therapy injections in an office setting. Am J Ophthalmol 2008; 145:879-882.
93. Fintak DR, Shah GK, Blinder KJ, et al. Incidence of endophthalmitis related to intravitreal injection of bevacizumab and ranibizumab. Retina 2008; 28:1395-1399.
94. Moshfeghi AA, Rosenfeld PJ, Flynn HW, Jr., et al. Endophthalmitis after intravitreal vascular [corrected] endothelial growth factor antagonists: a six-year experience at a university referral center. Retina 2011; 31:662-668.
95. Shah CP, Garg SJ, Vander JF, et al. Outcomes and risk factors associated with endophthalmitis after intravitreal injection of antivascular endothelial growth factor agents. Ophthalmology 2011; 118:2028-2034.
96. Mason JO 3rd, White MF, Feist RM, et al. Incidence of acute onset endophthalmitis following intravitreal bevacizumab (Avastin) injection. Retina 2008; 28:564-567.
97. Meyer CH, Michels S, Rodrigues EB, et al. Incidence of rhegmatogenous retinal detachments after intravitreal antivascular endothelial factor injections. Acta Ophthalmol 2011; 89:70-75.
98. Cunningham ET, Jr., Feiner L, Chung C, et al. Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular agerelated macular degeneration. Ophthalmology 2011; 118:2447-2452.
99. Coco RM, Sanabria MR, Hernandez AG, Fernandez Munoz M. Retinal pigment epithelium tears in age-related macular degeneration treated with antiangiogenic drugs: a controlled study with long follow-up. Ophthalmologica 2012; 228:78-83.
100. Sharei V, Hohn F, Kohler T, et al. Course of intraocular pressure after intravitreal injection of 0.05 mL ranibizumab (Lucentis). Eur J Ophthalmol 2010; 20:174-179.
101. Choi DY, Ortube MC, McCannel CA, et al. Sustained elevated intraocular pressures after intravitreal injection of bevacizumab, ranibizumab, and pegaptanib. Retina 2011; 31:1028-1035.
102. Bayar SA, Altinors DD, Kucukerdonmez C, Akova YA. Severe corneal changes following intravitreal injection of bevacizumab. Ocul Immunol Inflamm 2010; 18:268-274.
103. Scappaticci FA, Skillings JR, Holden SN, et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 2007; 99:1232-1239.
104. Ranpura V, Hapani S, Chuang J, Wu S. Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials. Acta Oncol 2010; 49:287-297.
105. Carneiro AM, Costa R, Falcao MS, et al. Vascular endothelial growth factor plasma levels before and after treatment of neovascular age-related macular degeneration with bevacizumab or ranibizumab. Acta Ophthalmol 2012; 90:e25-e30.
106. Muether PS, Hermann MM, Viebahn U, et al. Vascular endothelial growth factor in patients with exudative age-related macular degeneration treated with ranibizumab. Ophthalmology 2012; 119:2082-2086.
107. Leung DW, Cachianes G, Kuang WJ, et al. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989; 246:1306-1309.
108. Keck PJ, Hauser SD, Krivi G, et al. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 1989; 246:1309-1312.
109. Tam BY, Wei K, Rudge JS, et al. VEGF modulates erythropoiesis through regulation of adult hepatic erythropoietin synthesis. Nat Med 2006; 12:793-800.
110. Wang YQ, Guo X, Qiu MH, et al. VEGF overexpression enhances striatal neurogenesis in brain of adult rat after a transient middle cerebral artery occlusion. J Neurosci Res 2007; 85:73-82.
111. Zhang Z, Chopp M. Vascular endothelial growth factor and angiopoietins in focal cerebral ischemia. Trends Cardiovasc Med 2002; 12:62-66.
112. Zachary I. Signaling mechanisms mediating vascular protective actions of vascular endothelial growth factor. Am J Physiol Cell Physiol 2001; 280: C1375-C1386.
113. Kilickap S, Abali H, Celik I. Bevacizumab, bleeding, thrombosis, and warfarin. J Clin Oncol 2003; 21:3542; author reply 3.
114. Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992; 359:843-845.
115. Rosenstein JM, Mani N, Silverman WF, Krum JM. Patterns of brain angiogenesis after vascular endothelial growth factor administration in vitro and in vivo. Proc Natl Acad Sci U S A 1998; 95:7086-7091.
116. Meyer T, Robles-Carrillo L, Robson T, et al. Bevacizumab immune complexes activate platelets and induce thrombosis in FCGR2A transgenic mice. J Thromb Haemost 2009; 7:171-181.
117. Curtis LH, Hammill BG, Schulman KA, Cousins SW. Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for agerelated macular degeneration. Arch Ophthalmol 2010; 128:1273-1279.
118. Olea JL, Tunon J. Patients with neovascular age-related macular degeneration in Spain display a high cardiovascular risk. Eur J Ophthalmol 2012; 22:404-411.
119. Wong TY, Klein R, Sun C, et al. Age-related macular degeneration and risk for stroke. Ann Intern Med 2006; 145:98-106.
120. Cackett P, Cheung N, Wong TY. Age-related macular degeneration and mortality from cardiovascular disease or stroke. Br J Ophthalmol 2008; 92:1564.